In Belmora LLC v. Bayer Consumer Care AG,1 the U.S. Court of Appeals for the Fourth Circuit is faced with novel issues about the reach of the Lanham Act. The case arose from Bayer's filing of a petition to cancel Belmora's registered trademark FLANAX on the grounds that Belmora's use of that mark deceives consumers into believing that its FLANAX pain relief product is from the same source as the FLANAX product that Bayer has sold in Mexico for over four decades.

Please click here to continue reading the full text of this article

Originally published in BNA's Patent, Trademark & Copyright Journal, 01/01/2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.